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Use of Antidiabetic drugs during pregnancy
among U.S. women with Livebirth
deliveries in the Mini-Sentinel system
Katrina Mott1* , Marsha E. Reichman2, Sengwee Toh3, Caren Kieswetter2, Katherine Haffenreffer3 and
Susan E. Andrade4
Abstract
Background: As the prevalence of diabetes mellitus increases in the population, the exposure to antidiabetic drugs
(ADDs) during pregnancies is expected to grow, as has been seen over the last decade. The objective of this study
was to estimate the prevalence of ADD use during pregnancy among women in the Mini-Sentinel Distributed
Database (MSDD) who delivered a liveborn infant.
Methods: We identified qualifying livebirth pregnancies among women aged 10 to 54 years in the MSDD from
2001 to 2013. ADD use was estimated using outpatient pharmacy dispensing claims and days-supplied among
three cohorts: all livebirth pregnancies, pregnancies among women with pre-existing diabetes, and pregnancies
among women without prior ADD use.
Results: Among the 1.9 million pregnancies in the MSDD that resulted in a livebirth from 2001 to 2013, 4.4% were
exposed to an ADD. Of the 15,606 pregnancies (0.8%) with pre-existing diabetes, 92.8% were also exposed during
the pregnancy period. The most commonly used product in these pregnancies was insulin (75.6% of pregnancies).
In contrast, in pregnancies of women without prior ADD use, the most commonly used products were glyburide
and insulin, and most of these users were diagnosed with gestational diabetes.
Conclusions: Patterns of ADD use during pregnancy described here, along with changes in disease incidence and
management, highlight the importance of continuing surveillance of ADD utilization patterns and examining the
safety and effectiveness of these products in pregnancy.
Keywords: Pregnancy, Glyburide, Insulin, Gestational diabetes
Key points
1. From 2001 to 2013, 4.4% (n = 82,676) of live birth
pregnancies in the database were exposed to an
antidiabetic drug (ADD).
2. Over the gestational period, increases in ADD use
are mostly due to increases in use of two agents:
glyburide and insulin.
3. Of pregnancies among women with pre-existing
diabetes, 93% were dispensed an ADD during the
gestational period.
4. In pregnancies among women without prior ADD
use, insulin and sulfonylureas were the most
commonly used agents.
Introduction
There is a need for ongoing routine surveillance of
medication use during pregnancy, as new drugs become
available and prescribing trends and recommendations
change. Up to 9% of pregnant women have pre-existing
diabetes mellitus or develop gestational diabetes, which
may require drug therapy [1–6]. The prevalence of ges-
tational diabetes has been increasing over the last two
decades [1–6]. Unmanaged diabetes in pregnancy, lead-
ing to hyperglycemia, is associated with excess risk of
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macrosomia, stillbirths, and other neonatal complica-
tions [7].
The American Congress of Obstetricians and Gynecol-
ogists (ACOG) Practice Bulletin #30 in 2001 recom-
mended adding insulin if glycemic control could not be
achieved with nutritional therapy alone for women with
gestational diabetes [8]. Several randomized controlled
trials and observational studies, which compared glybur-
ide to insulin for gestational diabetes, showed the two
therapies to be comparable in achieving glycemic control
[9]. In 2013, the ACOG guidelines were revised (Practice
Bulletin #137) to state that insulin and oral ADDs (e.g.,
glyburide and metformin) are equally efficacious, and
could be considered for first-line therapy [9]. The use of
glyburide increased during this time period [9]. The
American Diabetes Association guidelines (2015) lists
insulin and metformin as preferred treatments, and
states that glyburide may be used, but may have a higher
rate of neonatal hypoglycemia and macrosomia [10].
For women with pre-existing diabetes who become
pregnant, an ACOG Practice Bulletin (#60) in 2005 and
a consensus statement by the American Diabetes Associ-
ation in 2008 recommend insulin as the primary method
of glycemic control [7, 11]. The ACOG guideline recom-
mended stopping oral ADDs and switching to insulin as
early in the pregnancy as possible [11].
The goal of this paper is to describe patterns of ADD
use during pregnancy in the large cohort of livebirth
pregnancies in the Mini-Sentinel Distributed Database
(MSDD) from 2001 to 2013.
Methods
Data source
The U.S. Food and Drug Administration (FDA) Mini-
Sentinel pilot project was a collaboration to build an ac-
tive surveillance system for medical product safety [12].
This pilot project, which has now transitioned to the
full-fledged Sentinel system, built a distributed database
of insurance claims and administrative data using a com-
mon data model to create the MSDD. As of July 2014,
the database included medical claims with procedure
and diagnosis codes, pharmacy claims, and enrollment
and demographic information for more than 178 million
individuals. For this project, 15 data partners contributed
to the analysis. The data partners performed standard-
ized data analysis using an analytic tool developed by the
Mini-Sentinel Operations Center and returned the
summary-level results to the Operations Center for final
aggregation and analysis. Data partners contributed data
for varying time periods throughout the study period,
with the majority of included pregnancies occurring after
2009. This project was conducted under FDA’s public
health authority and was not under the purview of the
Institutional Review Board.
Analytic tool
This analysis utilized the Mini-Sentinel pregnancy ana-
lytic tool to identify women aged 10 to 54 years who
delivered a liveborn infant between 2001 and 2013 [13].
It identified maternal characteristics of the eligible preg-
nancies, including year of delivery, maternal age, pre/
post-term birth, and pre-existing diabetes. To be in-
cluded, women had to be enrolled in a health plan of-
fered by an MSDD data partner which included medical
and pharmacy benefits for at least 480 days prior to de-
livery. A woman could contribute multiple pregnancies
if she met these criteria. Pregnancy periods, including
trimesters, were calculated using a validated algorithm
developed in the Medication Use in Pregnancy Risk
Evaluation Program (MEPREP) and Post-Licensure Rapid
Immunization Safety Monitoring (PRISM) projects to esti-
mate gestational age at birth [14–16].
After cohort identification, the analytic tool deter-
mined medication exposure based on outpatient phar-
macy dispensing claims for ADDs, identified by National
Drug Code, during and prior to the pregnancy period.
Exposure was defined using both dispense dates and
days-supplied information in the MSDD. First trimester
was defined as days 0 to 90 (with day 0 calculated as the
estimated start of the pregnancy), the second trimester
as days 91 to 180, and the third trimester as day 181
through the admit date of the hospital admission for de-
livery. All drug dispensing events were counted, so that
a pregnancy could be counted in multiple drug exposure
categories.
Cohorts
For this analysis, three cohorts were identified. First, the
cohort of all eligible livebirth pregnancies was defined
using the criteria described above to capture any qualify-
ing livebirth pregnancy during the time period. Second,
the cohort of pregnancies among women with pre-
existing diabetes was identified as any pregnancy for
which the mother had a dispensing of a non-metformin
ADD or a dispensing of metformin with a diabetes diag-
nosis code (ICD-9-CM 250.x) at any time in the 183 days
prior to the start of pregnancy. We excluded metformin
use that lacked a diabetes diagnosis code because met-
formin is also used to treat non-diabetic conditions, such
as polycystic ovary syndrome. The third cohort consisted
of pregnancies in women without any ADD dispensing
in the 183 days prior to the start of pregnancy. To esti-
mate the trends of ADD use for gestational diabetes, we
identified pregnancies in the third cohort as women who
were dispensed an ADD during the pregnancy period,
and who met the following definition of gestational
diabetes: a diagnosis code for gestational diabetes (ICD-
9-CM 648.8) in the 2nd or 3rd trimester and no prior
diabetes mellitus diagnosis.
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Statistical analysis
In the three cohorts of pregnancies, we identified ADD
use and specific agent use any time during pregnancy
and by trimester. The percent of pregnancies with use of
each product are presented to compare use across prod-
ucts, and through the pregnancy trimesters. We also
stratified use by age group to identify differences in use
patterns by maternal age. Prevalence ratios (PR) were
calculated for the primary findings.
Results
The cohort of all livebirth pregnancies consisted of 1,895,
604 live birth pregnancies in 1.6 million women between
2001 and 2013, identified with the pregnancy algorithm
in the MSDD (Table 1). For most pregnancies (58.3%),
women were between ages 25 to 34 at the time of deliv-
ery. Approximately 7.7% of deliveries had a code for
preterm birth, while 13.7% had a code for post-term
birth. Of the total cohort, 4.4% (n = 82,676) of pregnan-
cies had exposure to an ADD. Table 2 displays the use
of ADD products by trimester in the total pregnancy
cohort. Use of any ADD increased from the 1st to 3rd
trimester (2.1 to 3.4% of pregnancies, prevalence ratio =
1.59, 95%CI (1,57, 1.61)). This increase was due primar-
ily to an increase in use of glyburide (0.1 to 1.4%, PR =
13.91, 95%CI (13.27, 14.57)) and increase in use of insu-
lin (0.7 to 1.8%, PR = 2.72, 95%CI (2.67, 2.78)) over the
course of the pregnancy period. In the 90 days before
pregnancy, 1.6% of pregnancies had exposure to metfor-
min, but use of metformin decreased to 0.5% by the 3rd
trimester. As expected, exposure to ADDs increased
with increasing maternal age (Table 3). The trend was
similar for the three drug categories with the most use
(metformin, sulfonylureas, and insulin).
There were 15,606 pregnancies among women with
pre-existing diabetes, of which 92.8% had an ADD expos-
ure during the pregnancy (Table 4). Compared to all
livebirth pregnancies, pregnancies with pre-existing dia-
betes were more likely to be among older women (32.7%
of the pre-existing diabetes cohort vs. 21.9% of the total
cohort was over age 35), and were more likely to have a
pre-term birth (19.9% vs. 7.7%) (Table 1). In this cohort
of women with pre-existing diabetes, the prevalence of
ADD use remained steady over the course of pregnancy
(85.4, 82.5, and 83.4% in each successive trimester, re-
spectively), as shown in Table 4. The most commonly
used product during pregnancy was insulin (75.6% of
pregnancies), followed by metformin as the second most
commonly used product (37.7%) (PR = 2.00, 95%CI
(1.96, 2.05), Fig. 1). Metformin use among these preg-
nancies decreased over the course of pregnancy, from
35.7% in the first trimester to 14.5% in the third trimes-
ter (Table 4, Fig. 1). Sulfonylureas were also commonly
used: glyburide at any time in 12.8% of pregnancies (n =
2001) and consistently across trimesters (7.0% of preg-
nancies in the 1st trimester to 8.1% in the 3rd), and
glipizide at any time in 3.8% of pregnancies. Notably,
pre-term delivery was more common among women
with pre-existing diabetes (19.9% vs. 7.7% in total co-
hort), so the third trimesters would, on average, be
shorter than the second and first trimesters -- effectively
having fewer days on which a prescription could be
filled. There are large differences in the distribution of
drugs used by maternal age group in this cohort
(Table 5). The proportion of pregnancies exposed to
metformin was more than twice as high in women over
age 40 compared to the proportion in women under age
25 (PR = 2.82, 95%CI (2.56, 3.13)). Similarly, the propor-
tion of pregnancies exposed to a sulfonylurea was 30%
over age 45, compared to less than 7% in pregnancies in
women under age 20. Between 70 and 80% of
Table 1 Characteristics of the cohort of all livebirth pregnancies
and the cohort of pregnancies among women with pre-existing
diabetes between 2001 and 2013 in the MSDD
Characteristic Cohort of all livebirth
pregnancies
Cohort of pregnancies
in women with
pre-existing diabetes
Total unique
women with
a pregnancy
episode
1,598,705 14,216
Total unique
pregnancies
1,895,604 (100.00%) 15,606 (100.00%)
Total unique
pregnancies
with ADD
82,676 (4.4%) 14,488 (92.8%)
Total unique
pregnancies
without ADD
1,812,928 (95.6%) 1118 (7.2%)
Maternal age at
delivery, years
< 20
20–24
25–29
30–34
35–39
40–44
45–54
115,584 (6.1%)
260,013 (13.7%)
495,250 (26.1%)
610,703 (32.2%)
329,080 (17.4%)
76,995 (4.1%)
7979 (0.4%)
404 (2.6%)
1608 (10.3%)
3545 (22.7%)
4949 (31.7%)
3745 (24.0%)
1082 (6.9%)
273 (1.8%)
Year of delivery 2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
41,870 (2.21%)
62,345 (3.29%)
62,310 (3.29%)
61,544 (3.25%)
64,573 (3.41%)
68,056 (3.59%)
122,674 (6.47%)
146,443 (7.73%)
246,203 (12.99%)
275,835 (14.55%)
263,694 (13.91%)
252,272 (13.31%)
227,785 (12.02%)
245 (1.57%)
4.62 (2.96%)
492 (3.15%)
585 (3.75%)
581 (3.72%)
626 (4.01%)
1040 (6.66%)
1271 (8.14%)
1946 (12.47%)
2330 (14.93%)
2132 (13.66%)
2107 (13.50%)
1789 (11.46%)
Any code for
preterm birth
146,523 (7.7%) 3108 (19.9%)
Any code for
postterm birth
259,572 (13.7%) 309 (2.0%)
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pregnancies in women under age 45 with pre-existing
diabetes were exposed to insulin.
Among pregnancies without prior use of any ADD in
the 183 days before last menstrual period (LMP), the
most commonly used ADDs in pregnancy were sulfonyl-
ureas, followed by insulin and metformin (Fig. 2). In this
cohort, as expected for gestational diabetes, exposure to
ADDs increased over the course of pregnancy with most
use occurring in the 3rd trimester when the diagnosis is
made (reflected by the use of sulfonylureas and insulin).
However, a proportion of pregnancies without prior use
of any ADD did not meet both criteria of our gestational
Table 2 Antidiabetic Drug use, by trimester, in the cohort of all livebirth pregnancies during 2001–2013 in the MSDD
Use in the 90 Days
Before Pregnancy
Any Use During
Pregnancy
Any Use, First
Trimester
Any Use, Second
Trimester
Any Use, Third
Trimester
Total unique pregnancies 1,895,604 (100%) 1,895,604 (100%) 1,895,604 (100%) 1,895,604 (100%) 1,895,122 (100%)
Drug Class or Product
Use of Any Drug 38,017 (2.0%) 82,676 (4.4%) 40,013 (2.1%) 35,587 (1.9%) 63,483 (3.4%)
Alpha-Glucosidase Inhibitors 21 (<0.1%) 149 (<0.1%) 19 (< 0.1%) 24 (<0.1%) 129 (<0.1%)
Amylin Analog 55 (<0.1%) 48 (<0.1%) 46 (<0.1%) 9 (< 0.1%) 5 (< 0.1%)
Metformin 30,194 (1.6%) 32,757 (1.7%) 29,431 (1.6%) 15,827 (0.8%) 9897 (0.5%)
Dipeptidyl Peptidase-4 Inhibitors 226 (< 0.1%) 242 (< 0.1%) 227 (< 0.1%) 87 (< 0.1%) 50 (< 0.1%)
Glucagon-like Peptide-1 Agonists 403 (<0.1%) 333 (<0.1%) 316 (<0.1%) 77 (<0.1%) 32 (<0.1%)
Meglitinide Analogs 45 (<0.1%) 44 (<0.1%) 43 (<0.1%) 12 (<0.1%) 2 (<0.1%)
Sulfonylureas – Use of Any Drug 2018 (0.1%) 28,240 (1.5%) 2748 (0.1%) 6325 (0.3%) 26,234 (1.4%)
Glimepiride 312 (<0.1%) 280 (<0.1%) 255 (<0.1%) 97 (<0.1%) 61 (<0.1%)
Glipizide 675 (<0.1%) 768 (< 0.1%) 617 (<0.1%) 316 (<0.1%) 218 (<0.1%)
Glyburide 976 (0.1%) 27,269 (1.4%) 1868 (0.1%) 5905 (0.3%) 25,973 (1.4%)
Tolazamide 80 (<0.1%) 82 (<0.1%) 82 (<0.1%) 53 (<0.1%) 23 (<0.1%)
Thiazolidinediones 965 (0.1%) 874 (0.1%) 841 (<0.1%) 274 (<0.1%) 123 (<0.1%)
Combination Products 565 (<0.1%) 633 (<0.1%) 520 (<0.1%) 204 (<0.1%) 155 (<0.1%)
Insulin – Any Injectable Insulin 7351 (0.4%) 34,476 (1.8%) 12,289 (0.7%) 18,028 (0.9%) 33,447 (1.8%)
Rapid-acting 5842 (0.3%) 25,959 (1.4%) 10,074 (0.5%) 14,602 (0.8%) 24,705 (1.3%)
Intermediate-acting 1803 (0.1%) 26,103 (1.4%) 6607 (0.4%) 11,824 (0.6%) 24,745 (1.3%)
Long-acting 2394 (0.1%) 4834 (0.3%) 2846 (0.2%) 2791 (0.2%) 3436 (0.2%)
Other-acting 598 (<0.1%) 1556 (0.1%) 854 (0.1%) 794 (0.1%) 976 (0.1%)
Table 3 Antidiabetic Drug use, by maternal age, in all livebirth pregnancies during 2001–2013 in the MSDD
< 20 years 20–24 years 25–29 years 30–34 years 35–39 years 40–44 years 45–54 years
Total unique pregnancies 115,584 (100%) 260,013 (100%) 495,250 (100%) 610,703 (100%) 329,080 (100%) 76,995 (100%) 7979 (100%)
Drug product/Class
Any Antidiabetic Drug 1004 (0.87%) 5227 (2.01%) 18,775 (3.79%) 30,327 (4.97%) 20,788 (6.32%) 5874 (7.63%) 681 (8.53%)
Alpha-Glucosidase Inhibitors 4 (0.00%) 10 (0.00%) 31 (0.01%) 54 (0.01%) 30 (0.01%) 18 (0.02%) 2 (0.03%)
Amylin Analog 1 (0.00%) 4 (0.00%) 15 (0.00%) 19 (0.00%) 6 (0.00%) 3 (0.00%) 0 (0.00%)
Metformin 294 (0.25%) 1839 (0.71%) 8616 (1.74%) 12,809 (2.10%) 7238 (2.20%) 1687 (2.19%) 274 (3.43%)
Dipeptidyl Peptidase-4 Inhibitors 1 (0.00%) 4 (0.00%) 34 (0.01%) 69 (0.01%) 83 (0.03%) 30 (0.04%) 21 (0.26%)
Glucagon-like Peptide-1 Receptor
Agonists
4 (0.00%) 12 (0.00%) 58 (0.01%) 109 (0.02%) 98 (0.03%) 36 (0.05%) 16 (0.20%)
Meglitinide Analogs 1 (0.00%) 8 (0.00%) 8 (0.00%) 13 (0.00%) 9 (0.00%) 3 (0.00%) 2 (0.03%)
Sulfonylureas 237 (0.21%) 1452 (0.56%) 5542 (1.12%) 10,151 (1.66%) 8012 (2.43%) 2570 (3.34%) 276 (3.46%)
Thiazolidinediones 17 (0.01%) 69 (0.03%) 208 (0.04%) 268 (0.04%) 196 (0.06%) 73 (0.09%) 43 (0.54%)
Combination Products 10 (0.01%) 55 (0.02%) 117 (0.02%) 197 (0.03%) 177 (0.05%) 52 (0.07%) 25 (0.31%)
Insulin 590 (0.51%) 2562 (0.99%) 6986 (1.41%) 11,868 (1.94%) 9392 (2.85%) 2813 (3.65%) 265 (3.32%)
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diabetes algorithm definition: a diagnosis code for
gestational diabetes in the 2nd or 3rd trimester and no
prior diabetes mellitus diagnosis (5.8% of sulfonylurea-
exposed pregnancies, 14.4% of insulin-exposed pregnan-
cies, and 50.2% of metformin-exposed pregnancies).
Discussion
In the MSDD cohort of livebirth pregnancies from 2001
to 2013, 4.4% were exposed to an ADD during preg-
nancy. Use of insulin and glyburide increased in preva-
lence over the pregnancy period, which is likely due to a
combination of newly diagnosed gestational diabetes and
a switch to these treatments from other oral drugs
among women with pre-existing diabetes. In pregnancies
among the women who might have gestational diabetes
based on their ADD use pattern (i.e. no ADD use prior
to pregnancy with ADD initiation during pregnancy),
not all of the women met our gestational diabetes defin-
ition based on the algorithm described above. We sus-
pect two possible explanations account for the women
not meeting the definition: 1) they had untreated dia-
betes mellitus prior to pregnancy and were started on
ADD therapy during pregnancy. Therefore, the algo-
rithm appropriately excluded these women from being
assigned a gestational diabetes indicator; or 2) they were
clinically diagnosed and treated for gestational diabetes
Table 4 Antidiabetic drug use, by trimester, in livebirth pregnancies among women with pre-existing diabetes during 2001–2013 in
the MSDD
Use in the 90 Days
Before Pregnancy
Any Use During
Pregnancy
Any Use, First
Trimester
Any Use, Second
Trimester
Any Use, Third
Trimester
Total unique pregnancies 15,606 (100%) 15,606 (100%) 15,606 (100%) 15,606 (100%) 15,594 (100%)
Drug Product/Class
Use of Any Drug 13,847 (88.7%) 14,488 (92.8%) 13,322 (85.4%) 12,876 (82.5%) 12,998 (83.4%)
Metformin 6024 (38.6%) 5886 (37.7%) 5572 (35.7%) 3533 (22.6%) 2257 (14.5%)
Sulfonylureas – Any Drug 2018 (12.9%) 2803 (18.0%) 1916 (12.3%) 1532 (9.8%) 1414 (9.1%)
Glipizide 675 (4.3%) 596 (3.8%) 573 (3.7%) 270 (1.7%) 91 (0.6%)
Glyburide 976 (6.3%) 2001 (12.8%) 1097 (7.0%) 1162 (7.5%) 1268 (8.1%)
Thiazolidinediones 965 (6.2%) 800 (5.1%) 786 (5.0%) 258 (1.7%) 104 (0.7%)
Combination Products 565 (3.6%) 502 (3.2%) 480 (3.1%) 166 (1.1%) 73 (0.5%)
Insulin 7351 (47.1%) 11,796 (75.6%) 9625 (61.7%) 10,776 (69.1%) 11,328 (72.6%)
Fig. 1 Antidiabetic drug use, by trimester, in the cohort of pregnancies among women with pre-existing diabetes during 2001–2013 in the
MSDD. † 90 days prior is the period of 90 days prior to the calculated start of pregnancy based on the pregnancy period algorithm using livebirth
delivery claim codes. 1st Tri, 2nd Tri, and 3rd Tri refer to the gestational trimesters, also calculated using the pregnancy period algorithm based
on delivery codes. Individual pregnancies could be counted in multiple gestational terms and for multiple drug categories. ‡Other category
includes alpha-glucosidase inhibitors, meglitinide analogs, amylin analog, DPP-4 inhibitors, GLP-1 receptor agonists, thiazolidinediones, and
combination products
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but a claim with the gestational diabetes diagnosis code
was not filed with their insurance. Errors in coding or
claims may also be responsible for some proportion of
this discrepancy.
Many of the findings in this analysis were similar to
those of previous work, particularly in the MEPREP
database [17]. Specifically, the proportion of pregnancies
with metformin, glyburide, and insulin exposure were
comparable in the two studies. This similarity is ex-
pected, since 8 out of the 15 data partners in this ana-
lysis also participated in MEPREP. In the cohort of
women with pre-existing diabetes in this study, at least
83% of pregnancies were exposed to an ADD in the sec-
ond or third trimester, in contrast to the 56.5% reported
by MEPREP although different definitions of prior ADD
exposure were used. The MEPREP study included ADD
use within 120 days prior to pregnancy and may have in-
cluded women using metformin for reasons other than
glycemic control who would not be expected to continue
use during pregnancy [17].
The major strengths of this study are the size of the
pregnancy cohort and the ability to define sub-cohorts
based on prior diagnoses or prescriptions dispensed. The
database consists of mostly privately insured individuals,
so the findings may be generalized to the broader popu-
lation of women with commercial insurance in the U.S.
Some of the limitations of this study are as follows. As
with any claims-based surveillance of prescription drug
Table 5 Antidiabetic drug use, by maternal age, in livebirth pregnancies among women with pre-existing diabetes during 2001–
2013 in the MSDD
< 20 years 20–24 years 25–29 years 30–34 years 35–39 years 40–44 years 45–54 years
Total unique pregnancies 404 (100%) 1608 (100%) 3545 (100%) 4949 (100%) 3745 (100%) 1082 (100%) 273 (100%)
Drug product/Class
Any Antidiabetic Drug 365 (90.35%) 1419 (88.25%) 3262 (92.02%) 4635 (93.66%) 3536 (94.42%) 1010 (93.35%) 261 (95.60%)
Alpha-Glucosidase Inhibitors 0 (0.00%) 2 (0.12%) 8 (0.23%) 9 (0.18%) 3 (0.08%) 4 (0.37%) 2 (0.73%)
Amylin Analog 1 (0.25%) 3 (0.19%) 14 (0.39%) 17 (0.34%) 6 (0.16%) 3 (0.28%) 0 (0.00%)
Metformin 87 (21.53%) 311 (19.34%) 1102 (31.09%) 1906 (38.51%) 1722 (45.98%) 598 (55.27%) 160 (58.61%)
Dipeptidyl Peptidase-4 Inhibitors 1 (0.25%) 3 (0.19%) 32 (0.90%) 66 (1.33%) 75 (2.00%) 27 (2.50%) 19 (6.96%)
Glucagon-like Peptide-1 Receptor
Agonists
3 (0.74%) 11 (0.68%) 56 (1.58%) 103 (2.08%) 94 (2.51%) 34 (3.14%) 15 (5.49%)
Meglitinide Analogs 1 (0.25%) 7 (0.44%) 8 (0.23%) 13 (0.26%) 9 (0.24%) 3 (0.28%) 2 (0.73%)
Sulfonylureas 28 (6.93%) 184 (11.44%) 512 (14.44%) 907 (18.33%) 833 (22.24%) 255 (23.57%) 84 (30.77%)
Thiazolidinediones 14 (3.47%) 64 (3.98%) 181 (5.11%) 246 (4.97%) 187 (4.99%) 68 (6.28%) 40 (14.65%)
Combination Products 6 (1.49%) 37 (2.30%) 84 (2.37%) 155 (3.13%) 155 (4.14%) 43 (3.97%) 22 (8.06%)
Insulin 321 (79.46%) 1237 (76.93%) 2701 (76.19%) 3767 (76.12%) 2868 (76.58%) 789 (72.92%) 113 (41.39%)
Fig. 2 Antidiabetic drug use, by trimester, in the cohort of pregnancies among women with no prior ADD use during 2001–2013 in the MSDD. †
1st Tri, 2nd Tri, and 3rd Tri refer to the three gestational trimesters, calculated using the pregnancy period algorithm based on delivery codes.
Individual pregnancies could be counted in multiple gestational terms and for multiple drug categories. ‡ Other category includes alpha-
glucosidase inhibitors, meglitinide analogs, amylin analog, DPP-4 inhibitors, GLP-1 receptor agonists, thiazolidinediones, and
combination products
Mott et al. BMC Pregnancy and Childbirth          (2019) 19:441 Page 6 of 8
use, this study assumed that prescriptions dispensed
were taken by the women. Exposure was defined by the
days supplied from each dispensing. Additionally, preg-
nancies were counted in every drug category to which
they were exposed, but this study did not determine how
many pregnancies were exposed to multiple medications,
or the reason for changes in treatment. Furthermore, the
results are limited to the pregnancies with a livebirth
outcome, and do not include exposures in women who
had miscarriages, stillbirths, or terminations. At the time
of this study, we were unable to define women’s parity.
Out-of-pocket payments for prescriptions are not re-
corded in claims data and are a source of missing data.
The definition for pre-gestational diabetes is not vali-
dated, and misclassification of diabetes status is possible.
Finally, data partners contributed data for different time
periods, with most contributing data for recent years, so
these estimates most closely reflect use in the 2007–
2013 time period. This limitation means we could not
analyze trends robustly over time, although some general
observations are similar to the trends others have de-
scribed in similar populations [17, 18]. Among all live-
birth pregnancies in our study, the use of glyburide
increased over this time period studied, from less than
0.5% of pregnancies to approximately 2%; this increase
was not seen in pregnancies among women with pre-
existing diabetes (data not shown). For women with pre-
existing diabetes, the prevalence of metformin use has
increased (20.4 to 41.5%) over the study period, while
use of insulin decreased (89.8 to 77.3%). Interpreting
these trends requires the assumption that the women
enrolled in the databases contributing data in the early
years are similar to the women enrolled in the contribut-
ing databases in recent years, which may not be a valid
assumption.
The rates of diabetes mellitus and gestational diabetes
have increased over the last two decades [1, 2, 4, 6, 19].
Obstetric practice recommendations in the treatment of
gestational diabetes has also changed, as noted by others
and as reflected in updated guidelines [8, 11, 18]. These
trends suggest that a larger proportion of pregnancies
are likely exposed to antidiabetic drugs in the coming
years. Changes in disease incidence and management
highlight the need for continuing surveillance of ADD
utilization patterns and examining the safety and effect-
iveness of these products in pregnancy.
Conclusions
This study finds that from 2001 to 2013, 4.4% of preg-
nancies were exposed to an antidiabetic drug. Almost all
pregnancies among women with pre-existing diabetes
continue treatment during the pregnancy, with 75% be-
ing treated with insulin. Among pregnancies in women
without pre-existing diabetes, sulfonylureas (particularly
glyburide) and insulin were the most commonly used
products to treat gestational diabetes. This observational
cohort of pregnancies receiving ADD treatment high-
light the importance of continuing surveillance of ADD
utilization patterns and examining drug safety and ef-
fectiveness among pregnant women.
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